Registration Successful...
null you have successfully logged registered and logged in
LAIV Composition & Replication

FLUMIST expresses the same surface antigens as the influenza virus strain1,2

FLUMIST expresses the same surface antigens as the influenza virus strain1,2

The vaccine virus strains express the surface proteins of hemagglutinin (HA) and neuraminidase (NA) from the wild-type viruses identified by the WHO that are expected to circulate during the season1-3

  • HA is responsible for the binding of the influenza virus to the host cell that it is infecting1,2
  • NA allows the release of newly developed virions (virus particles) from the host cell1,2
Live Attenuated Influenza Vaccine CompositionLive Attenuated Influenza Vaccine Composition

With at least 5 attenuating points in each strain of FLUMIST vaccine, the odds of reversion to wild-type influenza are approximately 1 in 100 quintillion replication cycles (1x1020 replication cycles), more than a millennium in time5

Help prevent flu this season with FLUMIST, a live attenuated influenza vaccine (LAIV) engineered to stimulate an immune response1,6-8

  • Replicates in the nose to induce a broad immune response that closely resembles natural immunity4
Live Attenuated Influenza Vaccine, Engineered to Stimulate an Immune Response and Prevent FluLive Attenuated Influenza Vaccine, Engineered to Stimulate an Immune Response and Prevent Flu

FLUMIST is a live attenuated vaccine.1 Other routinely administered live attenuated vaccines include those for MMR, varicella, and rotavirus.9

IMPORTANT SAFETY INFORMATION

  • Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
  • In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
  • Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
  • If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of the potential benefits and risks
  • The effectiveness of FLUMIST has not been studied in immunocompromised persons
  • The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of FLUMIST
  • FLUMIST may not protect all individuals receiving the vaccine
  • The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full Prescribing Information for FLUMIST, including Patient Information.

You may report side effects related to AstraZeneca products.